Woolcock Jane G, Grivell Rosalie M, Dodd Jodie M
Women's and Babies' Division, Discipline of Obstetrics and Gynaecology, The University of Adelaide, Women's and Children's Hospital, 72 King William Road, Adelaide, Australia, 5006.
Cochrane Database Syst Rev. 2017 Nov 7;11(11):CD011371. doi: 10.1002/14651858.CD011371.pub2.
Increased ultrasound surveillance of twin pregnancies has become accepted practice due to the higher risk of complications. There is no current consensus however as to the method and frequency of ultrasound monitoring that constitutes optimal care.
To systematically review the effects of different types and frequency of ultrasound surveillance for women with a twin pregnancy on neonatal, fetal and maternal outcomes.
We searched Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (all searched 11 August 2017), and reference lists of retrieved studies.
Randomised and quasi-randomised trials (including those published in abstract form) comparing the effects of described antenatal ultrasound surveillance regimens in twin pregnancies. Trials using a cluster-randomised design would have been eligible for inclusion in this review but none were identified. Trials using a cross-over design are not eligible for inclusion in this review.Different types and frequencies of ultrasound testing (for fetal surveillance and detection of specific problems) compared with each other and also compared with no testing. For example, an intervention might comprise a specific approach to ultrasound examination with dedicated components to detect twin-specific pathology. Different interventions could also include a specific type of surveillance at different intervals or different combinations at the same intervals.In this review we only found one study looking at fetal growth (biometry) and Doppler ultrasounds at 25, 30 and 35 weeks' gestation versus fetal growth alone.
Two review authors independently assessed trials for inclusion and quality, and extracted data. We checked data for accuracy.
We included one trial of 526 women with a twin pregnancy of two viable twins, with no known morphological abnormality, in this review. The trial compared women receiving fetal growth and Doppler ultrasounds at 25, 30 and 35 weeks' gestation to fetal growth alone. We judged the included study to be at low risk of bias however the risk of performance and detection bias were unclear.The primary outcome was the perinatal mortality rate (after randomisation), for which there was no evidence of a clear difference between the fetal growth + Doppler and the fetal growth alone groups (risk ratio (RR) 0.88, 95% confidence interval (CI) 0.32 to 2.41, low-quality evidence) with similar rates in both groups (seven events in the Dopper + fetal growth group and eight in the fetal growth alone group). No clear differences were seen between the two regimens for the other outcomes in this review: stillbirth (RR 0.67, 95% CI 0.11 to 3.99), neonatal death (RR 1.01, 95% CI 0.29 to 3.46, low-quality evidence), gestational age at birth (weeks) (mean difference 0.10, 95% CI -0.39 to 0.59, moderate-quality evidence), infant requiring ventilation (RR 0.86, 95% CI 0.59 to 1.25), admission to special care or intensive care units (RR 0.96, 95% CI 0.88 to 1.05), caesarean section (any) (RR 1.00, 95% CI 0.81 to 1.23, high-quality evidence), elective caesarean section (RR 1.06, 95% CI 0.77 to 1.47), emergency caesarean section (RR 0.93, 95% CI 0.66 to 1.32), induction of labour (RR 1.10, 95% CI 0.80 to 1.50, moderate-quality evidence) or antenatal hospital admission (RR 0.96, 95% CI 0.80 to 1.15, high-quality evidence). The number of preterm births before 28 weeks' gestation was not reported in the included study. For the mortality-related outcomes, event numbers were small.The included study did not report the majority of our maternal and infant secondary outcomes. Infant outcomes not reported included fetal acidosis, Apgar scores less than 7 at five minutes and preterm birth before 37 and 34 weeks' gestation. The maternal outcomes; length of antenatal hospital stay, timely diagnosis of significant complications, rate of preterm, prelabour rupture of membranes and women's level of satisfaction with their care were not reported. The study did not classify twin pregnancies according to their chorionicity. An awareness of the chorionicity may have improved applicability of this data set.We downgraded outcomes assessed using GRADE for imprecision of effect estimates.
AUTHORS' CONCLUSIONS: This review is based on one small study which was underpowered for detection of rare outcomes such as perinatal mortality, stillbirth and neonatal death.There is insufficient evidence from randomised controlled trials to inform best practice for fetal ultrasound surveillance regimens when caring for women with a twin pregnancy. More studies are needed to evaluate the effects of currently used ultrasound surveillance regimens in twin pregnancies. Future research could report on the important maternal and infant outcomes as listed in this review.
由于双胎妊娠并发症风险较高,增加超声监测已成为公认的做法。然而,目前对于构成最佳护理的超声监测方法和频率尚无共识。
系统评价不同类型和频率的超声监测对双胎妊娠妇女的新生儿、胎儿和母体结局的影响。
我们检索了Cochrane妊娠与分娩试验注册库、ClinicalTrials.gov、世界卫生组织国际临床试验注册平台(ICTRP)(均检索于2017年8月11日)以及检索到的研究的参考文献列表。
比较所述产前超声监测方案对双胎妊娠影响的随机和半随机试验(包括以摘要形式发表的试验)。采用整群随机设计的试验本可纳入本综述,但未检索到。采用交叉设计的试验不符合纳入本综述的条件。相互比较以及与不进行超声检查相比的不同类型和频率的超声检查(用于胎儿监测和特定问题的检测)。例如,一项干预措施可能包括一种特定的超声检查方法,具有专门的组成部分以检测双胎特异性病理情况。不同的干预措施还可能包括在不同间隔进行的特定类型监测或在相同间隔进行的不同组合监测。在本综述中,我们仅找到一项研究,该研究比较了在妊娠25、30和35周时进行胎儿生长和多普勒超声检查与仅进行胎儿生长监测的情况。
两位综述作者独立评估试验是否纳入及质量,并提取数据。我们检查了数据的准确性。
本综述纳入了一项针对526例双胎妊娠妇女的试验,双胎均存活且无已知形态学异常。该试验比较了在妊娠25、30和35周时接受胎儿生长和多普勒超声检查的妇女与仅进行胎儿生长监测的妇女。我们判断纳入的研究偏倚风险较低,但实施和检测偏倚风险尚不清楚。主要结局是围产期死亡率(随机分组后),胎儿生长+多普勒组与仅胎儿生长组之间没有明显差异的证据(风险比(RR)0.88,95%置信区间(CI)0.32至2.41,低质量证据),两组发生率相似(多普勒+胎儿生长组7例事件,仅胎儿生长组8例事件)。本综述中其他结局在两种方案之间未观察到明显差异:死产(RR 0.67,95%CI 0.11至3.99)、新生儿死亡(RR 1.01,95%CI 0.29至3.46,低质量证据)、出生孕周(周)(平均差0.10,95%CI -0.39至0.59,中等质量证据)、需要通气的婴儿(RR 0.86,95%CI 0.59至1.25)、入住特殊护理或重症监护病房(RR 0.96,95%CI 0.88至1.05)、剖宫产(任何情况)(RR 1.00,95%CI 0.81至1.23,高质量证据)、择期剖宫产(RR 1.06,95%CI 0.77至1.47)、急诊剖宫产(RR 0.93,95%CI 0.66至1.32)、引产(RR 1.10,95%CI 0.80至1.50,中等质量证据)或产前住院(RR 0.96,95%CI 0.80至1.15,高质量证据)。纳入研究未报告妊娠28周前的早产数量。对于与死亡率相关的结局,事件数量较少。纳入研究未报告我们大多数的母婴次要结局。未报告的婴儿结局包括胎儿酸中毒、5分钟时Apgar评分低于7分以及妊娠37周和34周前的早产。未报告的母体结局包括产前住院时间、重大并发症的及时诊断、早产率、胎膜早破率以及妇女对其护理的满意度。该研究未根据双胎妊娠的绒毛膜性进行分类。了解绒毛膜性可能会提高该数据集的适用性。我们因效应估计不精确而对使用GRADE评估的结局进行了降级。
本综述基于一项小型研究,该研究检测围产期死亡率、死产和新生儿死亡等罕见结局的能力不足。随机对照试验中没有足够的证据为双胎妊娠妇女的胎儿超声监测方案提供最佳实践依据。需要更多研究来评估目前使用的超声监测方案对双胎妊娠的影响。未来的研究可以报告本综述中列出的重要母婴结局。